Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Actuate Therapeutics, Inc. Common stock

Healthcare US ACTU

1.94USD
0.12(6.59%)

Last update at 2026-06-04T20:00:00Z

Day Range

1.811.96
LowHigh

52 Week Range

1.5811.99
LowHigh

Fundamentals

  • Previous Close 1.82
  • Market Cap62.12M
  • Volume59064
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax -22.22785M -27.28453M -24.74462M -20.15940M
Minority interest - - - -
Net income -22.22785M -27.28533M -24.74462M -20.15940M
Selling general administrative 12.20M 6.48M 3.27M 3.82M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation - - - -
Ebit - -27.30404M - -
Ebitda -22.49531M -25.16073M - -
Depreciation and amortization - 2.14M - -
Non operating income net other - - - -
Operating income -22.49531M -25.16073M -24.97383M -20.20681M
Other operating expenses 22.49M 25.16M - -
Interest expense 0.02M 0.02M 0.04M 0.02M
Tax provision - - - -
Interest income 0.29M 0.22M 0.35M 0.03M
Net interest income 0.27M 0.20M 0.31M 0.01M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.00080M 0.00080M - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 22.50M 25.16M 24.97M 20.21M
Cost of revenue - - - -
Total other income expense net 0.27M -2.12379M -0.07982M 0.04M
Discontinued operations - - - -
Net income from continuing ops -22.22785M -27.28533M -24.74462M -20.15940M
Net income applicable to common shares - - - -
Preferred stock and other adjustments - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total assets 14.04M 9.32M 3.00M 20.48M
Intangible assets - - - -
Earning assets - - - -
Other current assets 0.48M 0.57M 0.04M 0.03M
Total liab 6.11M 9.21M 102.62M 95.79M
Total stockholder equity 7.92M 0.10M -99.62651M -75.30543M
Deferred long term liab - - - -
Other current liab 4.18M 6.88M - -
Common stock 0.00002M 0.00002M - -
Capital stock 0.00002M 0.00002M 0.00000M 0.00000M
Retained earnings -154.60770M -132.37900M -105.09452M -80.34990M
Other liab - - - -
Good will - - - -
Other assets - - - -
Cash 13.16M 8.64M 2.96M 20.45M
Cash and equivalents - - - -
Total current liabilities 5.71M 8.80M 6.92M 4.34M
Current deferred revenue - - - -
Net debt -12.75443M -8.64162M - -
Short term debt - - - -
Short long term debt - - - -
Short long term debt total 0.40M 0.40M - -
Other stockholder equity 162.53M 132.48M - -
Property plant equipment - - - -
Total current assets 13.64M 9.21M 3.00M 20.48M
Long term investments - - - -
Net tangible assets - - - -
Short term investments - - - -
Net receivables - - - -
Long term debt - - - -
Inventory - - - -
Accounts payable 1.52M 1.92M 3.42M 2.13M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income - - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.39M 0.11M - -
Deferred long term asset charges - - - -
Non current assets total 0.39M 0.11M 0.00000M 0.00000M
Capital lease obligations - - - -
Long term debt total - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investments - - - -
Change to liabilities - - - -
Total cashflows from investing activities - - - -
Net borrowings 0.00000M 5.50M - -
Total cash from financing activities 23.72M 27.53M 4.13M 19.26M
Change to operating activities - - - -
Net income -22.22785M -27.28533M -24.74462M -20.15940M
Change in cash 4.52M 5.68M -17.49065M 1.46M
Begin period cash flow 8.64M 2.96M 20.45M 18.99M
End period cash flow 13.16M 8.64M 2.96M 20.45M
Total cash from operating activities -19.20625M -21.84265M -21.62517M -17.79409M
Issuance of capital stock 23.99M 23.96M 4.13M 19.26M
Depreciation - - - -
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock - 0.49M - -
Other cashflows from financing activities -0.30283M -1.93119M - -
Change to netincome - - - -
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital -3.04531M 1.10M 2.57M 1.73M
Stock based compensation 6.05M 2.00M 0.42M 0.65M
Other non cash items 0.02M 2.35M 0.04M 0.02M
Free cash flow -19.20625M -21.84265M -21.62517M -17.79409M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
ACTU
Actuate Therapeutics, Inc. Common stock		 0.12 6.59% 1.94 - - - 7.84
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

Actuate Therapeutics, Inc. Common stock

1751 River Run, Fort Worth, TX, United States, 76107

Key Executives

Name Title Year Born
Mr. Daniel M. Schmitt CEO, President & Director 1962
Dr. Andrew P. Mazar Ph.D. Co-Founder & COO 1962
Dr. Alan Kozikowski Ph.D. Scientific Founder and Advisor 1951
Mr. Paul J. Lytle CPA Chief Financial Officer 1968
Dr. Alan Kozikowski Ph.D. Scientific Founder and Advisor 1950

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.